ArticlePLoS pathogens2019
A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III.
Article in PLoS pathogens, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 42 citations in OpenAlex.
- Antibody-Dependent Enhancement in Flavivirus Infections: From Fc Receptor Signaling to Vaccine and Therapeutic Design.Viruses · 2026Review
- Potent Cross-Serotype Dengue Neutralization with Low ADE by AG-Strand-Targeting Anti-EDIII Antibodies.ACS omega · 2026Article
- Human germline-like monoclonal antibody against 5T4 enables potent ADC and CAR-T therapies for solid tumors.Acta pharmacologica Sinica · 2026Article
- An engineered IL-21 variant is a potent antitumor candidate for antitumor immunotherapy.Acta pharmacologica Sinica · 2026Article
- Antiviral agents for dengue virus.Virologica Sinica · 2025Review
- Dengue encephalitis: what's new?Current opinion in infectious diseases · 2025Review
- Human genetic variation shapes the antibody repertoire across B cell development.bioRxiv : the preprint server for biology · 2025Article
- Fluorescence Reduction Neutralization Test: A Novel, Rapid, and Efficient Method for Characterizing the Neutralizing Activity of Antibodies Against Dengue Virus.Current issues in molecular biology · 2025Article
- Monoclonal antibodies: From magic bullet to precision weapon.Molecular biomedicine · 2024Review
- An Engineered N-Glycosylated Dengue Envelope Protein Domain III Facilitates Epitope-Directed Selection of Potently Neutralizing and Minimally Enhancing Antibodies.ACS infectious diseases · 2024Article
- Dengue virus neutralizing antibody: a review of targets, cross-reactivity, and antibody-dependent enhancement.Frontiers in immunology · 2023Review
- Monoclonal antibody therapeutics for infectious diseases: Beyond normal human immunoglobulin.Pharmacology & therapeutics · 2022Review
- Charged Residue Implantation Improves the Affinity of a Cross-Reactive Dengue Virus Antibody.International journal of molecular sciences · 2022Article
- Peculiarities of Zika Immunity and Vaccine Development: Lessons from Dengue and the Contribution from Controlled Human Infection Model.Pathogens (Basel, Switzerland) · 2022Review
- Discovery of B-cell epitopes for development of dengue vaccines and antibody therapeutics.Medical microbiology and immunology · 2022Review
- Antibody Library Screening Using Yeast Biopanning and Fluorescence-Activated Cell Sorting.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Guidelines, Strategies, and Principles for the Directed Evolution of Cross-Reactive Antibodies Using Yeast Surface Display Technology.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines.Frontiers in immunology · 2022Review
- Flavivirus Entry Inhibitors.Advances in experimental medicine and biology · 2022Article
- Near-germline human monoclonal antibodies neutralize and protect against multiple arthritogenic alphaviruses.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 5 institutions in 3 countries.
Funding
Abstract
Dengue is the most widespread vector-borne viral disease caused by dengue virus (DENV) for which there are no safe, effective drugs approved for clinical use. Here, by using sequential antigen panning of a yeast antibody library derived from healthy donors against the DENV envelop protein domain III (DIII) combined with depletion by an entry defective DIII mutant, we identified a cross-reactive human monoclonal antibody (mAb), m366.6, which bound with high affinity to DENV DIII from all four DENV serotypes. Immunogenetic analysis indicated that m366.6 is a germline-like mAb with very few somatic mutations from the closest VH and Vλ germline genes. Importantly, we demonstrated that it potently neutralized DENV both in vitro and in the mouse models of DENV infection without detectable antibody-dependent enhancement (ADE) effect. The epitope of m366.6 was mapped to the highly conserved regions on DIII, which may guide the design of effective dengue vaccine immunogens. Furthermore, as the first germline-like mAb derived from a naïve antibody library that could neutralize all four DENV serotypes, the m366.6 can be a tool for exploring mechanisms of DENV infection, and is a promising therapeutic candidate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.